Among women aged 65 years or older with localized cervical cancer, those who underwent recommended surgery or radiation had significantly lower cervical cancer mortality and a higher 5-year survival ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic cervical cancer patients. The trial enrolled patients with confirmed ...

Complete response correlated with exceptional durability, with unreached median OS/PFS, 100% 24-month OS, and 84.6% 12-month PFS, suggesting profound long-term disease control in select patients.

New national data shows Australia is close to eliminating cervical cancer, with rates among young women dropping drastically.